Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 18Sarcoma 9Gastrointestinal 7Myeloid 6Lymphoid 6Genitourinary 6NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 15Thyroid Neoplasms 10Thyroid Cancer, Papillary 10Adenocarcinoma, Follicular 9Paraganglioma 4Adrenocortical Carcinoma 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Somatostatinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1

Interventions

gallium Ga 68 dotatate 290Y-octreotide, DOTA-Tyr(3)- 2tipifarnib 1pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1entrectinib 1entinostat 1arginyllysine 1Whole Body Imaging 1Vorinostat 1Temozolomide 1Tamoxifen 1Surveys and Questionnaires 1Radiotherapy 1Photochemotherapy 1Magnetic Resonance Spectroscopy 1LY2940680 1Fentanyl 1Doxorubicin 1Dihematoporphyrin Ether 1Dexamethasone 1Cisplatin 1Calcium Dobesilate 1Biological Factors 1Amino Acids 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Magnetic Resonance Spectroscopy × Endocrine × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡